|
|
Blood, 1 May 2006, Vol. 107, No. 9, pp. 3609-3616.
Prepublished online as a Blood First Edition Paper on December 29, 2005; DOI 10.1182/blood-2005-08-3301.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Role of endothelial heparanase in delayed-type hypersensitivity
Evgeny Edovitsky,
Immanuel Lerner,
Eyal Zcharia,
Tamar Peretz,
Israel Vlodavsky, and
Michael Elkin
From the Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, and the Cancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Heparanase is an endoglycosidase that cleaves heparan sulfate (HS), the main polysaccharide of the basement membrane (BM). HS is responsible for BM integrity and barrier function. Hence, enzymatic degradation of HS in the vascular subendothelial BM is a prerequisite for extravasation of immune cells and plasma components during inflammation. Here, we demonstrate a highly coordinated local heparanase induction upon elicitation of delayed-type hypersensitivity (DTH) reaction in the mouse ear. By monitoring in vivo activation of luciferase gene driven by the heparanase promoter, we demonstrate activation of heparanase transcription at an early stage of DTH. We report that heparanase is produced locally by the endothelium at the site of DTH-associated inflammation. Key DTH mediators, tumor necrosis factor- and interferon- , were found to induce heparanase in cultured endothelial cells. Endothelium emerges as an essential cellular source of heparanase enzymatic activity that, in turn, allows for remodeling of the vascular BM, increased vessel permeability, and extravasation of leukocytes and plasma proteins. In vivo administration of antiheparanase siRNA or an inhibitor of heparanase enzymatic activity effectively halted DTH inflammatory response. Collectively, our results highlight the decisive role of endothelial heparanase in DTH inflammation and its potential as a promising target for anti-inflammatory drug development.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. K. Masouleh, G. B. Ten Dam, M. K. Wild, R. Seelige, J. van der Vlag, A. L. Rops, F. G. Echtermeyer, D. Vestweber, T. H. van Kuppevelt, L. Kiesel, et al.
Role of the Heparan Sulfate Proteoglycan Syndecan-1 (CD138) in Delayed-Type Hypersensitivity
J. Immunol.,
April 15, 2009;
182(8):
4985 - 4993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Cohen-Kaplan, I. Doweck, I. Naroditsky, I. Vlodavsky, and N. Ilan
Heparanase Augments Epidermal Growth Factor Receptor Phosphorylation: Correlation with Head and Neck Tumor Progression
Cancer Res.,
December 15, 2008;
68(24):
10077 - 10085.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Abboud-Jarrous, R. Atzmon, T. Peretz, C. Palermo, B. B. Gadea, J. A. Joyce, and I. Vlodavsky
Cathepsin L Is Responsible for Processing and Activation of Proheparanase through Multiple Cleavages of a Linker Segment
J. Biol. Chem.,
June 27, 2008;
283(26):
18167 - 18176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Lerner, L. Baraz, E. Pikarsky, A. Meirovitz, E. Edovitsky, T. Peretz, I. Vlodavsky, and M. Elkin
Function of Heparanase in Prostate Tumorigenesis: Potential for Therapy
Clin. Cancer Res.,
February 1, 2008;
14(3):
668 - 676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. de Mestre, M. A. Staykova, J. R. Hornby, D. O. Willenborg, and M. D. Hulett
Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene1
J. Leukoc. Biol.,
November 1, 2007;
82(5):
1289 - 1300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Xu, J. Ding, G. Rao, J. Shen, R. A. Prinz, N. Rana, and W.P. Dmowski
Estradiol induces heparanase-1 expression and heparan sulphate proteoglycan degradation in human endometrium
Hum. Reprod.,
April 1, 2007;
22(4):
927 - 937.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
